These pharmacological intervention studies provide compelling evidence that the TGF‐β/SMAD2/3/STAT3 signaling pathway represents a critical upstream regulatory mechanism regulating C1R expression in GBM cells. The gene discussed is C1R; the disease is glioblastoma.